AV CONCEPT HOLD (00595.HK) said So Kevin Chi Heng ceased as chief operation officer and Ip Hing Lam became chief operating officer from 1 October 2026.
SKB BIO (06990.HK) said the NMPA accepted a seventh indication filing for sac-TMT, combined with pembrolizumab in first-line PD-L1-negative non-squamous NSCLC.
HENGRUI PHARMA (01276.HK) won NMPA approval for new indication of Remimazolam Tosilate for Injection: sedation during mechanical ventilation in intensive care.
On October 27, the HSTECH fell 1.48% and the HSI lost 0.73%. DUALITYBIO-B led Stock Connect decliners, down 27.93%, on HK$1.238 billion of southbound selling.
MINSHENG EDU (01569.HK) said the HKIAC tribunal upheld the claimants' RMB2,180,735,560.50 exit price and found the option validly exercised in 2021.
NAGACORP (03918.HK) appointed Yeap Chee Wan as an INED and a member of three board committees from 27 October 2026, with an annual fee of US$73,000.
On 27 October 2026, ANDRE JUICE (02218.HK) completed the acquisition of a 62.0611% stake in Ningbo Yongqiang for RMB 792.79 million and has consolidated it.
On 27 October 2026, CHUANGLIAN HOLD (02371.HK) said remitting HKD 20 million from China by dividend would cost HKD 2.1 million to 2.2 million, or 10.5% to 11%.
On 27 October 2026, LIVZON PHARMA (01513.HK) said its subsidiary won approval to test Tiange Dingxuan Granules for vestibular migraine, a first in China.
On 27 October 2026, SINO HOTELS (01221.HK) appointed Lau Ip Keung as an independent non-executive director for three years, with an annual fee of HKD 150,000.
On 27 October 2026, CHINA RE (01508.HK) said the CSRC approved its registration for a targeted issue of Domestic Shares, with the approval valid for 12 months.
On October 27, Hong Kong stocks weakened, the Hang Seng Index down 0.73% on turnover of 178.3 billion HKD and southbound net selling of 1.238 billion HKD.
On 27 October 2026, LIVZON PHARMA (01513.HK) said its subsidiary won a Drug Registration Certificate for Wandai Tang Granules, the first approved in China.
MICOT PHARMA-B (02335.HK) closed at HKD 14.14 on October 26, 2026, down 1.94% for the day. The company's shares were included in the Hang Seng Composite Index on September 7, 2026 and were accordingly added to Stock Connect, and the share price has fallen about 46.3% since inclusion.
After being included in the Stock Connect on 7 September, the southbound stake in Jinhai Medical Technology rose from 0.18% on the first day to 0.90% on 23 October, with about 47.715 million shares held worth approximately HK$177 million. In the first half of 2026, revenue reached SGD34.021 million, up 134.2% year on year, with revenue from minimally invasive surgical solutions and medical products surging 301.5% to account for 74.7% of total revenue.
HAICHANG HLDG (02255.HK) traded at HKD 0.265 intraday on Oct 27, down 1.85%; it left Stock Connect on Sept 7 and has risen 16.2% since; H1 revenue fell 21.9%.
